🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients

RecruitingPhase 2Ages 18 Years - 65 YearsAllThe First Affiliated Hospital of Soochow Universi…
NCT07400328 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study aims to see if a single intravenous infusion of a cell therapy called Amimestrocel injection can help prevent severe mouth sores (oral mucositis) in patients receiving a stem cell transplant. Patients getting a stem cell transplant often receive strong chemotherapy (with radiation and/or a drug called melphalan) that can cause painful mouth and gut sores, making eating difficult and increasing infection risk. Amimestrocel injection is made from human umbilical cord cells that may help reduce inflammation and promote healing. About 22 adult patients scheduled for this type of transplant at one hospital in China will receive the infusion 1-2 days before their stem cell transplant. Researchers will closely check for mouth sores, pain, and side effects for the first 28 days, and continue safety monitoring for 100 days. The main goal is to see if the treatment lowers the rate of

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Aged 18 to 65 years. 2. Planned to undergo myeloablative allogeneic hematopoietic stem cell transplantation. 3. The conditioning regimen must contain total body irradiation (TBI) and/or melphalan. 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 5. Adequate organ function defined as:Left ventricular ejection fraction (LVEF) ≥ 50%.Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN).Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 60 mL/min. 6. Voluntarily signs the informed consent form. Exclusion Criteria: 1. History of allergy to mesenchymal stem cells or any component of the Amimestrocel injection preparation. 2. Presence of active, uncontrolled bacterial, fungal, or viral infection. 3. History of other malignancies within the past 5 years, except for cured carcinoma in situ or basal cell skin cancer. 4. Pregnant or lactating women, or those planning pregnancy during the study period. 5. Previous receipt of any cell therapy product. 6. Severe psychiatric disorder or cognitive impairment that would limit the ability to provide informed consent or comply with study procedures. 7. Any condition that, in the investigator's judgment, makes the subject unsuitable for study participation.
💊

What it tests

  • Amimestrocel injection
📍

Where

1 site
First Affiliated Hospital of Soochow University
Suzhu, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy